July 1, 2022
Nihon Servier said on June 30 that it has submitted a new drug application for its antitumor enzyme agent pegaspargase, currently being developed in Japan as a treatment for acute lymphocytic leukemia and malignant lymphoma. The drug is a pegylated...read more